Audeo Oncology Inc. filed for a $60 million initial public offering (IPO) to support clinical trials of its products based on hyaluronic acid chemotransport technology (HyACT) for cancer. The HyACT platform is designed to boost the effectiveness of cancer drugs without increasing toxicity.